BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol 2015; 7(20): 2274-2291 [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Nikolova D, Trajkovska M, Trpcevska EN, Eftimov A, Jovanovik R, Janevska V. Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18–21 mutations. Romanian Journal of Internal Medicine 2022;60:153-159. [DOI: 10.2478/rjim-2022-0006] [Reference Citation Analysis]
2 Wu P, Guo L, Yu S, Zeng N, Liu Y, Yu J, Zhang Z, Lu K, Sun L, Wang C, Chang Y, Lu Y, Shen Y, Tai S, Chuang Y, Ho JA, Huang K, Wu Y, Liu T. Noninvasive assessment of liver function reserve with fluorescent dosimetry of indocyanine green. Biomed Opt Express 2022;13:1995. [DOI: 10.1364/boe.446749] [Reference Citation Analysis]
3 Kampalath R, Tran-Harding K, Do RKG, Mendiratta-Lala M, Yaghmai V. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. Magn Reson Imaging Clin N Am 2021;29:389-403. [PMID: 34243925 DOI: 10.1016/j.mric.2021.05.013] [Reference Citation Analysis]
4 Zhao S, Wang H. EVA1A Plays an Important Role by Regulating Autophagy in Physiological and Pathological Processes. Int J Mol Sci 2021;22:6181. [PMID: 34201121 DOI: 10.3390/ijms22126181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Sun G, Sun K, Shen C. Human nuclear receptors (NRs) genes have prognostic significance in hepatocellular carcinoma patients. World J Surg Oncol 2021;19:137. [PMID: 33941198 DOI: 10.1186/s12957-021-02246-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
6 Bogdanovic A, Bulajic P, Masulovic D, Bidzic N, Zivanovic M, Galun D. Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. Sci Rep 2021;11:4493. [PMID: 33627697 DOI: 10.1038/s41598-021-83868-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Aslam A, Do RKG, Chernyak V, Mendiratta-lala M. LI-RADS Imaging Criteria for HCC Diagnosis and Treatment: Emerging Evidence. Curr Hepatology Rep 2020;19:437-447. [DOI: 10.1007/s11901-020-00546-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12(10): 738-753 [PMID: 33200013 DOI: 10.4254/wjh.v12.i10.738] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
9 Chao X, Jia Y, Feng X, Wang G, Wang X, Shi H, Zhao F, Jiang C. A Case-Control Study of ADCY9 Gene Polymorphisms and the Risk of Hepatocellular Carcinoma in the Chinese Han Population. Front Oncol 2020;10:1450. [PMID: 32983975 DOI: 10.3389/fonc.2020.01450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Costa C, Teodoro M, Rugolo CA, Alibrando C, Giambò F, Briguglio G, Fenga C. MicroRNAs alteration as early biomarkers for cancer and neurodegenerative diseases: New challenges in pesticides exposure. Toxicol Rep 2020;7:759-67. [PMID: 32612936 DOI: 10.1016/j.toxrep.2020.05.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
11 Fumarola EM, Ierardi AM, Biondetti P, Savoldi AP, Grillo P, Gorga G, Coppola A, Carrafiello G. Follow-up of percutaneous microwave (MW) ablation of hepatic lesion: predictive value of CT at 24-h compared with CT at 1 month. Med Oncol 2020;37:41. [PMID: 32266568 DOI: 10.1007/s12032-020-01364-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Song SS, Ying JF, Zhang YN, Pan HY, He XL, Hu ZM, Wang HJ, Dou XB, Mou XZ. High expression of FOXO3 is associated with poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2020;19:3181-8. [PMID: 32256814 DOI: 10.3892/ol.2020.11430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
13 Wang Y, Zhao Y, Zhang X, Zhang A, Ma J. Long noncoding RNA LBX2-AS1 drives the progression of hepatocellular carcinoma by sponging microRNA-384 and thereby positively regulating IRS1 expression. Pathol Res Pract 2020;216:152903. [PMID: 32143907 DOI: 10.1016/j.prp.2020.152903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
14 Mendiratta-lala M, William M, Shampain K, Zhang A, Jo A, Moorman S, Aslam A, Mature K, Davenport M. MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review. Radiology: Imaging Cancer. 2020;2. [PMID: 33778692 DOI: 10.1148/rycan.2020190024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
15 Wang H, Lv Y, Wang C, Leng D, Yan Y, Blessing Fasae M, Madiha Zahra S, Jiang Y, Wang Z, Yang B, Bai Y. Systematic Analysis of Intestinal MicroRNAs Expression in HCC: Identification of Suitable Reference Genes in Fecal Samples. Front Genet 2019;10:687. [PMID: 31456816 DOI: 10.3389/fgene.2019.00687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Yun Z, Meng F, Jiang P, Yue M, Li S. microRNA-548b suppresses aggressive phenotypes of hepatocellular carcinoma by directly targeting high-mobility group box 1 mRNA. Cancer Manag Res 2019;11:5821-34. [PMID: 31417317 DOI: 10.2147/CMAR.S198615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Fan X, Song J, Zhao Z, Chen M, Tu J, Lu C, Wu F, Zhang D, Weng Q, Zheng L, Xu M, Ji J. Piplartine suppresses proliferation and invasion of hepatocellular carcinoma by LINC01391-modulated Wnt/β-catenin pathway inactivation through ICAT. Cancer Lett 2019;460:119-27. [PMID: 31207322 DOI: 10.1016/j.canlet.2019.06.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
18 Yi PS, Li Y, Yan S, Wu B, Lan C, Li JS. Surgery combined with post-operative trancatheter arterial chemoembolization improves survival of intermediate hepatocellular carcinoma. Scand J Gastroenterol 2019;54:240-5. [PMID: 30880503 DOI: 10.1080/00365521.2019.1577487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Lessne ML, Kesselman A, Suhocki PV. Interventional Procedures for Global Health Radiology. Radiology in Global Health 2019. [DOI: 10.1007/978-3-319-98485-8_24] [Reference Citation Analysis]
20 Walcott-Sapp S, Naugler S, Lim JY, Wagner J, Orloff SL, Farsad K, Kolbeck KJ, Kaufman J, Maynard E, Enestvedt CK, Mayo SC, Billingsley KG. Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center. J Gastrointest Oncol 2018;9:1074-83. [PMID: 30603126 DOI: 10.21037/jgo.2018.08.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Ahmed AF, Samreen N, Grajo JR, Zendejas I, Sistrom CL, Collinsworth A, Esnakula A, Shah JL, Cabrera R, Geller BS, Toskich BB. Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:1825-36. [PMID: 29052747 DOI: 10.1007/s00261-017-1354-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
22 Galun D, Bogdanovic A, Djokic Kovac J, Bulajic P, Loncar Z, Zuvela M. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative-intent surgery for hepatocellular carcinoma: experience from a developing country. Cancer Manag Res. 2018;10:977-988. [PMID: 29765248 DOI: 10.2147/cmar.s161398] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
23 Ren WW, Li DD, Chen X, Li XL, He YP, Guo LH, Liu LN, Sun LP, Zhang XP. MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy. Cell Death Dis 2018;9:547. [PMID: 29749374 DOI: 10.1038/s41419-018-0592-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
24 Su H, Li B, Zheng L, Wang H, Zhang L. Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma. Oncotarget. 2016;7:48401-48411. [PMID: 27351282 DOI: 10.18632/oncotarget.10269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
25 De Mattia E, Cecchin E, Polesel J, Bignucolo A, Roncato R, Lupo F, Crovatto M, Buonadonna A, Tiribelli C, Toffoli G. Genetic biomarkers for hepatocellular cancer risk in a caucasian population. World J Gastroenterol 2017; 23(36): 6674-6684 [PMID: 29085212 DOI: 10.3748/wjg.v23.i36.6674] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
26 Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract 2017;71:e12972. [DOI: 10.1111/ijcp.12972] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
27 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
28 Charach L, Zusmanovitch L, Charach G. Hepatocellular Carcinoma. Part 1: Epidemiology, Risk Factors, Pathogenesis, and Pathology. EMJ Hepatol 2017. [DOI: 10.33590/emjhepatol/10312421] [Reference Citation Analysis]
29 许佐明, 浦涧. CTLs相关的免疫疗法在肝癌治疗中的新前景. 世界华人消化杂志 2017; 25(15): 1389-1395 [DOI: 10.11569/wcjd.v25.i15.1389] [Reference Citation Analysis]
30 De Mattia E, Cecchin E, Polesel J, Lupo F, Tiribelli C, Crovatto M, Buonadonna A, Toffoli G. UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. Liver Int. 2017;37:1345-1353. [PMID: 28294511 DOI: 10.1111/liv.13411] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
31 Dong S, Wang Z, Wu L, Qu Z. Effect of surgical margin in R0 hepatectomy on recurrence-free survival of patients with solitary hepatocellular carcinomas without macroscopic vascular invasion. Medicine (Baltimore) 2016;95:e5251. [PMID: 27858885 DOI: 10.1097/MD.0000000000005251] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
32 Xue R, Meng Q, Li J, Feng J, Shi H. Worse or better?-Cirrhosis with hepatocellular carcinoma. Med Hypotheses 2016;97:85-7. [PMID: 27876136 DOI: 10.1016/j.mehy.2016.10.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
33 Yang E, Li X, Jin N. The chimeric multi-domain proteins mediating specific DNA transfer for hepatocellular carcinoma treatment. Cancer Cell Int 2016;16:80. [PMID: 27752239 DOI: 10.1186/s12935-016-0351-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
34 Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther 2016;33:699-714. [PMID: 27039186 DOI: 10.1007/s12325-016-0324-7] [Cited by in Crossref: 89] [Cited by in F6Publishing: 74] [Article Influence: 14.8] [Reference Citation Analysis]
35 Kelekis A, Filippiadis D. Computed Tomography and Ultrasounds for the Follow-up of Hepatocellular Carcinoma Ablation: What You Need to Know. Diagnostics (Basel) 2016;6:E9. [PMID: 26861398 DOI: 10.3390/diagnostics6010009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Nguyen K, Jack K, Sun W. Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases 2015;4:E1. [PMID: 28933381 DOI: 10.3390/diseases4010001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
37 Wu X, Deng L, Tang D, Ying G, Yao X, Liu F, Liang G. miR-615-5p prevents proliferation and migration through negatively regulating serine hydromethyltransferase 2 (SHMT2) in hepatocellular carcinoma. Tumour Biol 2016;37:6813-21. [PMID: 26662310 DOI: 10.1007/s13277-015-4506-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]